An observational study in Stress, Cognitive Change and Breast Cancer, sponsored by Thomas Jefferson University. Terminated at 1 site in United States. Open to female participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.
Sponsored by Thomas Jefferson University · Observational
Insufficient Staff
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Breast Neoplasms by Thomas Jefferson University — 4 open to participants now, 5 under way, none of them phase 3. Breast Neoplasms · Thomas Jefferson University.
Among the 20 studies in Breast Neoplasms by Thomas Jefferson University, this one is the only one that started in 2025, is one of 5 observational ones, and was the 18th registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →4 of the 20 studies in Breast Neoplasms by Thomas Jefferson University are open now, in 1 country. Recruiting first, the newest first:
Thomas Jefferson University · Sites in United States
Ages 18+ · Women only
Thomas Jefferson University · Sites in United States
Ages 18+ · Women only
Thomas Jefferson University · Sites in United States
Ages 18+
Thomas Jefferson University · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 40 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 1 · Phase 4 2
First in 2005; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 17 is below the median of 184 across 3,239 observational studies indexed under Breast Neoplasms.
Median enrollment 25 across the 15 interventional studies, 70 across the 5 observational. Of the 13 that completed or were terminated, 2 (15%) have results posted.
This tab as a report to print or save as PDF → With an account.
Thomas Jefferson University is the lead sponsor of 394 studies on the registry; 69 are open to participants now.
Of its 45 completed or terminated interventional studies of FDA-regulated products, 21 (47%) have results posted.
2 of the studies in Breast Neoplasms by Thomas Jefferson University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05327608Thomas Jefferson UniversityTime Restricted Eating for the Improvement of Outcomes in Patients With Stage I-III Breast Cancer Receiving Chemotherapy Before Surgery | 2027-05-01 |
| NCT07737951Thomas Jefferson UniversityTai Chi for Reducing Aromatase Inhibitor-Induced Arthralgia | 2027-06 |
Add all 2 to your calendar (.ics) → With an account.
Among the 20 studies in Breast Neoplasms by Thomas Jefferson University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary goal of this project is to evaluate the feasibility of a 14-day mobile daily diary study among racially diverse breast cancer survivors. Further, the investigators will examine the validity and reliability of the daily stress and daily cognitive performance measures among breast cancer survivors. This pilot project will recruit 30 racially diverse breast cancer survivors (Asian, Black, Latina, and white; ages 40 and older; at least five years post-diagnosis) who are patients at the Sidney Kimmel Comprehensive Cancer Center. The daily diary survey questions will be available in English, Spanish, and Chinese to accommodate the preferred language of the target participants.
This is a pilot study that will assess the feasibility of a 14-day mobile daily diary survey to measure daily stress and cognitive performance among long-term breast cancer survivors.
Participants will be recruited from the Sidney Kimmel Cancer Center (SKCC) at Thomas Jefferson University (TJU). Potential participants will be identified via the SKCC/TJU Tumor Registry. Potential participants will be contacted with their cancer care team approval. Contact may be accomplished via an upcoming clinical appointment, phone, email, or MyChart (RLS) depending on the patient's communication preference or clinical team guidance.
Participants will start study procedures by completing the baseline survey using the mobile phone (day 1) to collect demographic and socioeconomic status information. Starting from day 2 to day 14, participants will complete the short morning (2-3 min) and slightly longer (5-7 min) evening mobile daily diary surveys. The morning survey asks questions about sleep, morning outlook, and anticipatory stress and positive experiences. The evening survey asks questions about the respondent's daily experiences (stressors, mood, physical symptoms). After each survey, respondents will complete three brief objective cognitive tasks. To minimize the risk of data breach, all the information from the survey will be stored on the password protected study mobile phone. The study mobile phones will be set up to ensure that it can only be used for study purposes, that is, participants are unable to make phone calls or connect to the internet with the study phone.
Findings from this pilot project will provide critical preliminary evidence regarding the feasibility of a mobile daily diary method among racially diverse breast cancer survivors, as well as the reliability and validity of the important measures related to daily stress, daily cognitive performance, and daily cognitive problems in racially diverse populations.
Breast cancer survivor who self-identifies as White, Black/African American, Latina, or Asian
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Individuals must meet all of the following inclusion criteria in order to be eligible to participate in the study:
Exclusion Criteria:
An individual who meets any of the following criteria will be excluded from participation in this study:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in the study will be given a mobile phone to complete the study. Participants will first complete the baseline survey using the mobile phone (day 1) to collect demographic and socioeconomic status information. Starting from day 2 to day 14, participants will complete the short morning (2-3 min) and slightly longer (5-7 min) evening mobile daily diary surveys. The morning survey asks questions about sleep, morning outlook, and anticipatory stress and positive experiences. The evening survey asks questions about the respondent's daily experiences (stressors, mood, physical symptoms). After each survey, respondents will complete three brief objective cognitive tasks. To minimize the risk of data breach, all the information from the survey will be stored on a password protected mobile phone which will be set up to ensure that participants are only able to use the phone for the study processes, not for phone calls or to connect to the internet.
Behavioral: Mobile Daily Diary
This study will include a 14-day daily diary survey in which participants will be expected to complete morning (\~5 minutes) and night (\~10 minutes) assessments using mobile phones provided by the research team.
Completion rate of the 14-day mobile daily diary survey
The feasibility of the mobile daily diary method will be based on calculating the percentage of completed daily diary surveys as well as percentages of completed morning and evening surveys. An accepted completion rate is predetermined at the level of 70% or higher
Time frame: Daily, from Day 2 through Day 15
predictive validity of the Daily Inventory of Stressful Experiences (DISE)
Predictive validity of the daily stressor exposure and severity will be conducted by testing the within-person and between-person associations between daily stressor exposure and severity with daily negative and positive affect, daily cognitive performance, and daily cognitive problems.
Time frame: Daily, from Day 2 through Day 15
predictive validity of Ambulatory Cognitive Assessment measures
Construct validity of the daily cognitive assessment measures will be assessed by conducting a multilevel confirmatory factor analysis (CFA) to assess the fit of our hypothesized measurement model.
Time frame: Twice Daily, from Day 2 through Day 15
internal reliability of Ambulatory Cognitive Assessment measures
Between-person reliability (higher intraclass correlation is expected, thus no calculation of within-person reliability) by calculating internal consistency (i.e., Cronbach's alpha) across all persons and days.
Time frame: Twice Daily, from Day 2 through Day 15
internal reliability of Cognitive Interference and Memory Lapses scale
Between-person reliability (higher intraclass correlation is expected, thus no calculation of within-person reliability) by calculating internal consistency (i.e., Cronbach's alpha) across all persons and days. PROMIS® v2.0 - Cognitive Function Scoring: * Raw Score Range: Varies by short form: * 4-item: 4-20 * 6-item: 6-30 * 8-item: 8-40 T-Score Range: \~22 to 65 * Mean: 50 * Standard Deviation: 10 Interpretation: * Higher scores indicate better cognitive function (i.e., less cognitive interference). * A T-score of 60 means one SD above average (better functioning); a T-score of 40 means one SD below average (more interference) Montreal Cognitive Assessment (MoCA) Scoring: * Total Score Range: 0-30 * Cutoff for Normal Cognition: ≥26 Interpretation: * Higher scores indicate better memory and cognitive function. * Scores between 22-25 suggest mild cognitive impairment (MCI). * Scores below 22 may indicate more significant memory or cognitive issues
Time frame: Daily, from Day 2 through Day 15
Ran from Oct 2025 to primary completion in Jun 2026, 8 months.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 28, 2026: primary completion Oct 2026 → Jun 2026 and completion Oct 2026 → Jun 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
Insufficient Staff
Insufficient Staff
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.